Validation of the Edmonton Symptom Assessment System: Ascites Modification.

Related Articles

Validation of the Edmonton Symptom Assessment System: Ascites Modification.

J Pain Symptom Manage. 2018 Mar 23;:

Authors: Mori M, Morita T, Yokomichi N, Nitto A, Takahashi N, Miyamoto S, Nishie H, Matsuoka J, Sakurai H, Ishihara T, Tarumi Y, Ogawa A

Abstract
CONTEXT: Few patient-reported outcomes are available to measure the symptoms associated with malignant-related ascites in patient care and clinical research. Although the Edmonton Symptom Assessment System: Ascites Modification (ESAS:AM) is a brief tool to measure symptoms associated with malignant-related ascites, it remains to be fully validated.
OBJECTIVES: To validate the ESAS:AM in Japanese cancer patients.
METHODS: We assessed the internal consistency, test-retest reliability, concurrent validity, and construct validity in 292 Japanese adult patients with cancer. They completed Japanese versions of the ESAS:AM, M.D. Anderson Symptom Inventory (MDASI), European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), and abdominal pain/ascites subscales of the EORTC Core Quality of Life Questionnaire pancreatic cancer module (QLQ-PAN26).
RESULTS: Cronbach's alpha coefficient of the ESAS:AM was 0.89. The intraclass correlation coefficient on test-retest examination of its total score was 0.93 (p<0.001). Pearson correlation coefficients of the total score of the ESAS:AM with the total score of the MDASI and abdominal pain/ascites subscales of the QLQ-PAN26 ranged from 0.44 to 0.81 (p<0.001); and those with global health status/quality of life and functional subscales of the EORTC QLQ-C30 ranged from -0.40 to -0.61 (p<0.001). The total scores of the ESAS:AM were significantly higher in 20 patients with symptomatic ascites (34 [standard deviation, 26]) than 267 patients without symptomatic ascites (23[19]) (p=0.018).
CONCLUSION: The ESAS:AM is a reliable and valid tool for measuring symptoms associated with malignant-related ascites, and can be used in daily patient care and future epidemiological studies and clinical trials.

PMID: 29581035 [PubMed - as supplied by publisher]

https://ift.tt/2pLlO5x